- Home
- ENTX vs LICN Comparison
ENTX vs LICN Comparison
Compare ENTX & LICN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ENTX
- LICN
- Stock Information
- Founded
- ENTX 2010
- LICN 2004
- Country
- ENTX Israel
- LICN China
- Employees
- ENTX N/A
- LICN N/A
- Industry
- ENTX Biotechnology: Biological Products (No Diagnostic Substances)
- LICN
- Sector
- ENTX Health Care
- LICN
- Exchange
- ENTX Nasdaq
- LICN Nasdaq
- Market Cap
- ENTX 69.6M
- LICN 22.9K
- IPO Year
- ENTX 2018
- LICN 2023
- Fundamental
- Price
- ENTX $1.85
- LICN $4.35
- Analyst Decision
- ENTX Strong Buy
- LICN
- Analyst Count
- ENTX 1
- LICN 0
- Target Price
- ENTX $10.00
- LICN N/A
- AVG Volume (30 Days)
- ENTX 55.8K
- LICN 147.8K
- Earning Date
- ENTX 05-09-2025
- LICN 01-01-0001
- Dividend Yield
- ENTX N/A
- LICN N/A
- EPS Growth
- ENTX N/A
- LICN 36.90
- EPS
- ENTX N/A
- LICN 55.10
- Revenue
- ENTX $99,000.00
- LICN $41,929,000.00
- Revenue This Year
- ENTX N/A
- LICN N/A
- Revenue Next Year
- ENTX N/A
- LICN N/A
- P/E Ratio
- ENTX N/A
- LICN $0.09
- Revenue Growth
- ENTX 607.14
- LICN 24.86
- 52 Week Low
- ENTX $1.30
- LICN $0.04
- 52 Week High
- ENTX $3.35
- LICN $7.55
- Technical
- Relative Strength Index (RSI)
- ENTX 40.63
- LICN 68.15
- Support Level
- ENTX $1.78
- LICN $4.52
- Resistance Level
- ENTX $2.00
- LICN $5.77
- Average True Range (ATR)
- ENTX 0.16
- LICN 0.45
- MACD
- ENTX -0.01
- LICN 0.23
- Stochastic Oscillator
- ENTX 19.44
- LICN 57.41
About ENTX Entera Bio Ltd.
Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to significantly shift a treatment paradigm. Its product candidates are; EB613 for the treatment of osteoporosis and EB612 for the treatment of hypoparathyroidism are first-in-class mini tablet formulations of synthetic human PTH (1-34) (teriparatide), designed to have differing pharmacokinetic, or PK, profiles.
About LICN Lichen China Limited
Lichen China Ltd is a holding company. The company, along with its subsidiaries provides financial and taxation solution services; education support services; and software and maintenance services. The company generates Majority revenue from Financial and taxation solution services.